Wednesday, July 18, 2012 6:21:21 PM
Historically, Elite was conceptualized as a company for developing drug delivery systems--such as controlled release and abuse resistant products 216 and 154 most notably.
....but Elite has additionally helped develop four products for what used to be SmithKline Beecham now GlaxoSmithKline.....yeah that huge 3rd largest Pharma company in the world right behind...Pfizer and J&J.
http://www.thefreelibrary.com/ELITE+LABORATORIES,+INC.+ANNOUNCES+RESEARCH+AND+DEVELOPMENT+AGREEMENT...-a018037091
So you want help in the Pharma space GSK probably would look upon us favorably given that Elite during its formative years helped GSK to a fair degree....
....another product for Novo-Nordisk and the two patents I've mentioned for Celgene that they have given to Novartis..
http://www.elitepharma.com/patents.asp
http://contracts.onecle.com/celgene/novartis.mkt.2000.04.19.shtml
So, if I have this correct the patent is in the hands of Novartis, but Elite would keep certain manufacturing rights for this product. Wouldn't that mean that Elite could manufacture methylphenidate currently??
Not to mention developing three cardiovascular, two anti-arthritic and one anti-diabetic product. And I don't know what happened to these drugs or what phases of development they are in......given the company almost went bankrupt but are out of those difficult waters.....
In other words, Elite was founded on being able to help develop niche products for itself and other pharmaceutical companies including Big Pharma!
Thus when Big Pharma patents were set to expire Elite was poised to help those very companies deliver existing drug products in novel ways that were devised by Elite!!!
DON'T MISS THIS...THIS IS ONE RESON ELITE'S PATENTS ARE SO IMPORTANT.
Thus, Big Pharma can focus on developing new products without the risk of losing so much revenue to generic pharmaceutical companies on existing drugs where patents are going to expire.......
Another plan was to have drug companies outsource their work via Elite.....which Elite is beginning to steadily increase currently!!
So Elite now has the Patent for Eli 216 that relates to ALL OPIOIDS and the company is about to become profitable this next year........all good for the PPS to come I realize.....
What the company has not been able to capitalize on YET....is helping Big Pharma maintain their niche products.....HOWEVER, given that this was the goal of the company from its inception......you can bet that this will be a HUGE focus in the next 2-3 years as the Government, Federal and societal powers that be continues to demand abuse resistant products.......thus once Elite markets their abuse resistant opioid line plural and Big Pharma is able to see first hand how beneficial Elite's abuse resistant technology is to them.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 09:15:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 08:43:45 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM